This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| NEUROD1 | |
|---|---|
| Name | NEUROD1 |
| Uniprot | P52875 |
| Omim | 601724 |
NEUROD1 is a neuronal differentiation transcription factor belonging to the basic helix-loop-helix family that directs neuronal and endocrine lineage specification. It functions as a sequence-specific DNA-binding protein that activates transcription programs during development of the central nervous system and pancreas. Research on NEUROD1 spans molecular biology, developmental neurobiology, and clinical genetics across institutions and model systems.
NEUROD1 acts as a transcriptional activator in neurogenesis and pancreatic islet development, integrating signals that influence neuronal fate decisions in regions like the cerebellum, hippocampus, cortex, and dorsal root ganglia. It heterodimerizes with other bHLH factors to regulate genes involved in neuronal differentiation, axon guidance, and synaptic function in contexts studied by laboratories at Harvard University, Stanford University, and the Max Planck Society. In the endocrine pancreas, NEUROD1 drives insulin gene expression and beta cell maturation in pathways intersecting research from Johns Hopkins University, Massachusetts General Hospital, and clinical consortia such as the International Diabetes Federation. NEUROD1-dependent programs are modulated by signaling cascades characterized in studies from Cold Spring Harbor Laboratory, Salk Institute, and the National Institutes of Health.
The NEUROD1 protein contains a basic helix-loop-helix domain that mediates DNA binding and dimerization, a transactivation domain that recruits coactivators, and conserved motifs identified by structural studies at institutions like European Molecular Biology Laboratory and University of Cambridge. The NEUROD1 gene maps to human chromosome loci described in genomic projects coordinated by the Human Genome Project, Genome Reference Consortium, and datasets curated by Ensembl and RefSeq. Mutational analyses published by research groups at UCLA, University of Oxford, and Karolinska Institutet document missense, nonsense, and regulatory variants that alter protein stability, nuclear localization, or DNA affinity, affecting developmental outcomes reported in clinical series at Boston Children's Hospital and Great Ormond Street Hospital.
NEUROD1 expression exhibits temporal-spatial patterns during embryogenesis with high levels in developing neural tube, islets of Langerhans, and sensory ganglia, detailed in atlases produced by the Allen Institute for Brain Science and consortiums including EMBL-EBI. Transcriptional control involves upstream regulators and enhancers characterized by chromatin studies from Broad Institute, Wellcome Sanger Institute, and epigenetics labs at University of California, San Francisco. Post-translational regulation via phosphorylation, ubiquitination, and interaction with signaling mediators such as kinases studied at MIT and Imperial College London modulate NEUROD1 stability and activity. Noncoding RNAs and microRNAs influencing NEUROD1 transcripts have been described by teams at Weill Cornell Medicine and Yale University.
Pathogenic variants in NEUROD1 are implicated in forms of monogenic diabetes and syndromes with neurological manifestations, with clinical case series reported from centers like Mayo Clinic, Cleveland Clinic, and Karolinska University Hospital. Loss-of-function alleles associate with neonatal diabetes and impaired insulin secretion documented in genotype-phenotype studies by the Genetics of Diabetes Audit and Research in Tayside Study (GoDARTS), while neurodevelopmental phenotypes have been described in cohorts assembled by European Society of Human Genetics and pediatric neurology services at Texas Children's Hospital. NEUROD1 is evaluated as a biomarker or therapeutic target in regenerative medicine, beta cell replacement strategies developed at University of Pennsylvania and neurorepair programs at University College London, and features in translational research funded by agencies including the National Institute of Diabetes and Digestive and Kidney Diseases.
NEUROD1 forms functional heterodimers with bHLH partners such as proteins characterized in protein interaction maps from STRING and studies originating at Protein Data Bank contributors; it recruits coactivators and chromatin remodelers identified in proteomics screens performed at Max Delbrück Center and European Proteomics Association collaborations. Interacting transcription factors and cofactors reported by labs at University of Tokyo, Peking University, and Seoul National University modulate target gene selection in neuronal and pancreatic contexts. NEUROD1 also interfaces with signaling molecules and epigenetic regulators investigated by consortia like the ENCODE Project and Roadmap Epigenomics Project.
Functional roles of NEUROD1 have been elucidated using knockout and transgenic mice generated by teams at The Jackson Laboratory, EMBL, and university facilities including University of California, Davis, revealing defects in cerebellar development, neuronal survival, and pancreatic islet formation. Zebrafish and Xenopus models studied at institutions such as University of Edinburgh and Karolinska Institutet have been used to assay conserved developmental functions, while in vitro differentiation systems employing human pluripotent stem cells are utilized in laboratories at Stanford University and Scripps Research to model beta cell and neuronal lineage specification. Gene editing and single-cell transcriptomics applied in recent studies by groups at Wellcome Sanger Institute and Broad Institute have refined understanding of NEUROD1-regulated networks and informed therapeutic strategies pursued by biotechnology companies and clinical collaborators including Regeneron and academic medical centers.
Category:Transcription factors